Core Viewpoint - The company has experienced growth in revenue and net profit in the first three quarters of the year, driven by an increase in overseas sales, and maintains a cautiously optimistic outlook for future overseas market growth [1][2] Group 1: Overseas Market Expansion - The company reported overseas revenue of approximately 1.4 billion yuan, representing a year-on-year increase of 42% [1] - As of the first half of the year, overseas revenue accounted for 58% of total revenue, with market expansion reaching over 90 countries and regions [1] - The company completed the acquisition of 51% of Spanish company CreoMedical S.L.U. in February [1] Group 2: Domestic Business Challenges - The company acknowledged that domestic centralized procurement is gradually being implemented, which poses short-term pressure on profits but may enhance market share in the long term [2] - The company noted a decline in revenue from high-margin products due to intensified price competition, with a 30% year-on-year decrease in domestic sales of microwave ablation products influenced by procurement policies in Heilongjiang [2] Group 3: Shareholder Concerns - Investors expressed concerns regarding the continuous reduction of shares by the major shareholder, Zhongke Investment, which may exert pressure on the stock price and lacks strategic support for the company [2] - The company clarified that the share reduction is a decision made by the shareholder based on personal judgment and emphasized its focus on core business development to maintain market confidence [2]